BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...VP of finance at Turnstone Biologics Inc.Vedanta Biosciences Inc. hired Mark Mullikin as CFO. The microbiome therapeutics...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

...and Epiva BioSciences to form a single microbiome therapeutics...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

...three years, Smith said. Finch also has a partnership with Takeda that includes development of microbiome therapeutics...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...to develop genetically engineered microbial medicines (GEMMs) that naturally colonize the gut. Other companies pursuing microbiome therapeutics...
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...of R&D and Anthony Colasin as SVP of business development. Pfost was acting CEO of MicroBiome Therapeutics LLC...
BioCentury | Sep 9, 2019
Finance

4Bio hopes to mix and match next-gen therapies with $150M fund

...back 8-12 early stage start-ups developing gene and cell therapies, RNA-based therapeutics, targeted therapies and microbiome therapeutics...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

...uncharted (see Box: “Live Regulation”). Table: Bug reports Trials of at least six live intestinal microbiome therapeutics...
...firm is open to adapting its suites for companies to manufacture anaerobic and spore-forming live microbiome therapeutics...
BioCentury | Aug 17, 2018
Company News

Rebiotix, Seres, Vedanta form microbiome policy group

...Inc. (Roseville, Minn.), Seres Therapeutics Inc. (NASDAQ:MCRB) and Vedanta Biosciences Inc. (Cambridge, Mass.) formed the Microbiome Therapeutics...
BioCentury | Jul 13, 2018
Financial News

Assembly raises $144M follow-on

...modulator is expected to enter Phase I testing next quarter. Last year, Assembly licensed preclinical microbiome therapeutics...
Items per page:
1 - 10 of 30
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...VP of finance at Turnstone Biologics Inc.Vedanta Biosciences Inc. hired Mark Mullikin as CFO. The microbiome therapeutics...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

...and Epiva BioSciences to form a single microbiome therapeutics...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

...three years, Smith said. Finch also has a partnership with Takeda that includes development of microbiome therapeutics...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...to develop genetically engineered microbial medicines (GEMMs) that naturally colonize the gut. Other companies pursuing microbiome therapeutics...
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...of R&D and Anthony Colasin as SVP of business development. Pfost was acting CEO of MicroBiome Therapeutics LLC...
BioCentury | Sep 9, 2019
Finance

4Bio hopes to mix and match next-gen therapies with $150M fund

...back 8-12 early stage start-ups developing gene and cell therapies, RNA-based therapeutics, targeted therapies and microbiome therapeutics...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

...uncharted (see Box: “Live Regulation”). Table: Bug reports Trials of at least six live intestinal microbiome therapeutics...
...firm is open to adapting its suites for companies to manufacture anaerobic and spore-forming live microbiome therapeutics...
BioCentury | Aug 17, 2018
Company News

Rebiotix, Seres, Vedanta form microbiome policy group

...Inc. (Roseville, Minn.), Seres Therapeutics Inc. (NASDAQ:MCRB) and Vedanta Biosciences Inc. (Cambridge, Mass.) formed the Microbiome Therapeutics...
BioCentury | Jul 13, 2018
Financial News

Assembly raises $144M follow-on

...modulator is expected to enter Phase I testing next quarter. Last year, Assembly licensed preclinical microbiome therapeutics...
Items per page:
1 - 10 of 30